Vertex Pharmaceuticals Incorporated (FRA:VX1)
336.80
+1.20 (0.36%)
Last updated: Sep 9, 2025, 9:00 AM CET
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.96B USD in the quarter ending June 30, 2025, with 12.06% growth. This brings the company's revenue in the last twelve months to $11.42B, up 10.46% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.42B
Revenue Growth
+10.46%
P/S Ratio
8.92
Revenue / Employee
$1.87M
Employees
6,100
Market Cap
86.74B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 78.30B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Rheinmetall AG | 10.67B |
Siemens Energy AG | 38.39B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Deutsche Bank Aktiengesellschaft | 30.07B |
Vertex Pharmaceuticals News
- 4 weeks ago - Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet - Seeking Alpha
- 4 weeks ago - Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade) - Seeking Alpha
- 4 weeks ago - Vertex Pharmaceuticals's Options Frenzy: What You Need to Know - Benzinga
- 4 weeks ago - 1.95M Reasons To Be Bullish On Vertex Pharmaceuticals Stock - Benzinga
- 4 weeks ago - Meet Reshma Kewalramani who joins the list of 100 Most Powerful People in Business 2025 alongside Jensen Huang, Sundar Pichai, and others - The Times of India
- 4 weeks ago - The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals’ Headquarters in Boston Seaport District - Wallstreet:Online
- 4 weeks ago - Vertex Pharmaceuticals Unusual Options Activity - Benzinga
- 5 weeks ago - 7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip - The Motley Fool